1
E therapy to either placebo or nothing (the control groups) [21]. Women were recruited in Estonia from 1999?001, and followed by annually mailed questionnaires in 2000?004. Detailed descriptions of the recruitment, inclusion and exclusion criteria, trial treatment, adherence, follow-up and trial outcomes as well as the content of information leaflets and trial questionnaires have been published el
1
Uscript. RL commented the manuscript. PV participated in the designing of the analysis and commented the manuscript. All authors read and approved the final manuscript. Acknowledgement This study was partly financed by Academy of Finland grant 2007?010 (decision number 115088). We thank all women who participated in the trial, the trial staff at clinical centres, and the staff at the National Inst
1
Same. Some women had symptoms variably (i.e. having one or more measurements without symptoms and then again reporting symptoms). Younger women did not systematically have more bothersome symptoms than older women. Comparing the proportions of women with bothersome symptoms at various times to those in the crosssectional analysis of Table 2 reveals relatively similar percentages. For comparison, w
1
Used. With the current knowledge on the mixed effect on diseases, it might be feasible to find a representative cohort of new menopausal women without HT for follow-up studies.8.9.10. 11.Conclusion There was a notable variability in the development of disturbing vasomotor symptoms over time in a selected group of women aged 50 -59. Population-based followup studies of untreated women would be usef
1
E therapy to either placebo or nothing (the control groups) [21]. Women were recruited in Estonia from 1999?001, and followed by annually mailed questionnaires in 2000?004. Detailed descriptions of the recruitment, inclusion and exclusion criteria, trial treatment, adherence, follow-up and trial outcomes as well as the content of information leaflets and trial questionnaires have been published el
1
Evelop and validate a Pregnancy Symptoms Inventory for use by health professionals. Methods: A list of symptoms was generated via expert consultation with health professionals. Focus groups were conducted with pregnant women. The inventory was tested for face validity and piloted for readability and comprehension. For test-re-test reliability, the tool was administered to the same women 2 to 3 day
1
Among all menopausal women (occurring in 16?2 of premenopausal, 39?7 of perimenopausal and 35?0* Correspondence: elina.hemminki@thl.fi 1 National Institute for Health and Welfare (THL), P.O. Box 3000271, Helsinki, Finland Full list of author information is available at the end of the articleof postmenopausal women). In a Finnish populationbased study by Hemminki et al. (1995), 28 of women aged
1
Foxcroft et al. BMC PregnancyT at www.biomedcentral.com/submitFoxcroft et al. BMC Pregnancy and Childbirth 2013, 13:3 http://www.biomedcentral.com/1471-2393/13/RESEARCH ARTICLEOpen AccessDevelopment and validation of a pregnancy symptoms inventoryKatie F Foxcroft1, Leonie K Callaway2, Nuala M Byrne3* and Joan WebsterAbstractBackground: Physical symptoms are common in pregnancy and are